5月7日,云顶新耀宣布其布地奈德肠溶胶囊(商品名:耐赋康)正式获得国家药品监督管理局(NMPA)同意,由附条件批准转为完全批准,取消了对蛋白尿水平的限制,用于治疗具有疾病进展风险的原发性免疫球蛋白A肾病(IgAN)成人患者,以减少肾功能损失。此次完全批准,意味着耐赋康®成为国内首个且唯一获得NMPA完全批准的IgA肾病对因治疗药物。耐赋康®是口服靶向布地奈德迟释胶囊,是靶向肠道的黏膜免疫调节剂。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.